Department of Neurology, University of Utah, Salt Lake City, UT, USA.
Department of Neurology, University of Utah, Salt Lake City, UT, USA; George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, UT, USA.
J Neuroimmunol. 2022 Jan 15;362:577761. doi: 10.1016/j.jneuroim.2021.577761. Epub 2021 Nov 2.
A retrospective, observational analysis of 47 patients with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder (AQP4-IgG+ NMOSD) enrolled at the University of Utah healthcare system was conducted. Visual acuity, neurological disability, and pain medication use were compared in relapsing versus non-relapsing patients. The median observation period was 3.6 years (range: 0.0-11.4 years); the annual relapse rate was 0.1376 (95% confidence interval: 0.0874, 0.191). Relapsing patients (n = 14) exhibited diminished visual acuity, clinically meaningful worsening of neurological disability, and greater pain medication use than non-relapsing patients (n = 33). Therapies that reduce the risk of relapses should be considered when making treatment decisions.
对在犹他大学医疗系统就诊的 47 例水通道蛋白 4 免疫球蛋白 G 阳性视神经脊髓炎谱系疾病（AQP4-IgG+NMOSD）患者进行了回顾性、观察性分析。比较了复发患者和非复发患者的视力、神经功能障碍和止痛药使用情况。中位观察期为 3.6 年（范围：0.0-11.4 年）；年复发率为 0.1376（95%置信区间：0.0874，0.191）。与非复发患者（n=33）相比，复发患者（n=14）的视力下降、神经功能障碍明显恶化和止痛药使用更多。在做出治疗决策时，应考虑使用可降低复发风险的疗法。
